BR112023004885A2 - Composto de fórmula (i), ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de telangiectasia hemorrágica hereditária (hht) em um indivíduo e composto para uso - Google Patents
Composto de fórmula (i), ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de telangiectasia hemorrágica hereditária (hht) em um indivíduo e composto para usoInfo
- Publication number
- BR112023004885A2 BR112023004885A2 BR112023004885A BR112023004885A BR112023004885A2 BR 112023004885 A2 BR112023004885 A2 BR 112023004885A2 BR 112023004885 A BR112023004885 A BR 112023004885A BR 112023004885 A BR112023004885 A BR 112023004885A BR 112023004885 A2 BR112023004885 A2 BR 112023004885A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- hht
- formula
- treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2015536.2A GB2600384A (en) | 2020-09-30 | 2020-09-30 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| PCT/EP2021/076811 WO2022069552A1 (en) | 2020-09-30 | 2021-09-29 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023004885A2 true BR112023004885A2 (pt) | 2023-04-18 |
Family
ID=73197201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023004885A BR112023004885A2 (pt) | 2020-09-30 | 2021-09-29 | Composto de fórmula (i), ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de telangiectasia hemorrágica hereditária (hht) em um indivíduo e composto para uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12466839B2 (https=) |
| EP (1) | EP4221713A1 (https=) |
| JP (1) | JP2023543993A (https=) |
| KR (1) | KR20230080448A (https=) |
| CN (1) | CN116419924A (https=) |
| AU (1) | AU2021352108B2 (https=) |
| BR (1) | BR112023004885A2 (https=) |
| CA (1) | CA3192433A1 (https=) |
| CL (1) | CL2023000926A1 (https=) |
| GB (1) | GB2600384A (https=) |
| IL (1) | IL301466A (https=) |
| MX (1) | MX2023002996A (https=) |
| WO (1) | WO2022069552A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| WO2026038045A1 (en) | 2024-08-15 | 2026-02-19 | Almac Discovery Limited | Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7910561B2 (en) | 2004-12-15 | 2011-03-22 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| EP1898903B8 (en) | 2005-06-10 | 2013-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2008011032A1 (en) | 2006-07-17 | 2008-01-24 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| JP2010512312A (ja) | 2006-12-06 | 2010-04-22 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害剤 |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| JP2011522048A (ja) | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｋｔ活性の阻害剤 |
| US8536193B2 (en) | 2008-06-03 | 2013-09-17 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| EP2116237A1 (en) | 2008-08-05 | 2009-11-11 | Polichem SA | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| EA201101186A1 (ru) | 2009-02-13 | 2012-04-30 | Байер Фарма Акциенгезельшафт | Конденсированные пиримидины |
| GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| HUE026323T2 (en) | 2011-04-07 | 2016-05-30 | Bayer Ip Gmbh | Imidazopyridazines as akt kinase inhibitors |
| EP3294314A4 (en) | 2015-05-15 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES |
| MX2020002611A (es) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Activador especifico de akt3 y usos del mismo. |
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
-
2020
- 2020-09-30 GB GB2015536.2A patent/GB2600384A/en not_active Withdrawn
-
2021
- 2021-09-29 KR KR1020237014688A patent/KR20230080448A/ko active Pending
- 2021-09-29 WO PCT/EP2021/076811 patent/WO2022069552A1/en not_active Ceased
- 2021-09-29 AU AU2021352108A patent/AU2021352108B2/en active Active
- 2021-09-29 BR BR112023004885A patent/BR112023004885A2/pt unknown
- 2021-09-29 CN CN202180066598.2A patent/CN116419924A/zh active Pending
- 2021-09-29 CA CA3192433A patent/CA3192433A1/en active Pending
- 2021-09-29 JP JP2023519016A patent/JP2023543993A/ja active Pending
- 2021-09-29 EP EP21789616.6A patent/EP4221713A1/en active Pending
- 2021-09-29 US US18/247,261 patent/US12466839B2/en active Active
- 2021-09-29 IL IL301466A patent/IL301466A/en unknown
- 2021-09-29 MX MX2023002996A patent/MX2023002996A/es unknown
-
2023
- 2023-03-29 CL CL2023000926A patent/CL2023000926A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240092801A1 (en) | 2024-03-21 |
| AU2021352108A1 (en) | 2023-05-11 |
| CN116419924A (zh) | 2023-07-11 |
| GB2600384A (en) | 2022-05-04 |
| WO2022069552A1 (en) | 2022-04-07 |
| CL2023000926A1 (es) | 2023-11-03 |
| EP4221713A1 (en) | 2023-08-09 |
| JP2023543993A (ja) | 2023-10-19 |
| MX2023002996A (es) | 2023-05-03 |
| KR20230080448A (ko) | 2023-06-07 |
| CA3192433A1 (en) | 2022-04-07 |
| GB202015536D0 (en) | 2020-11-11 |
| AU2021352108B2 (en) | 2026-04-02 |
| US12466839B2 (en) | 2025-11-11 |
| IL301466A (en) | 2023-05-01 |
| AU2021352108A9 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012585A2 (pt) | Inibidores de formas mutantes de egfr | |
| BR112022001600A2 (pt) | Regimes de dosagem para inibidores do fator d de complemento oral | |
| BR112023004885A2 (pt) | Composto de fórmula (i), ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de telangiectasia hemorrágica hereditária (hht) em um indivíduo e composto para uso | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk | |
| BRPI0518360A2 (pt) | composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| BR112022008575A2 (pt) | Bloqueadores de canal iônico carregado e métodos para uso | |
| JOP20200130B1 (ar) | مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية | |
| BR112018005904A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
| EA202192669A1 (ru) | Твердые формы ингибитора бета-лактамазы для пероральной доставки и их применения | |
| BR112023001615A2 (pt) | Tratamento para enxaqueca | |
| BR112018005870A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
| BR112021017809A2 (pt) | Bloqueadores de canais iônicos substituídos por éster e métodos para uso | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| BR112022022452A2 (pt) | Inibidores de il4i1 e métodos de uso | |
| BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
| BR112022014861A2 (pt) | Métodos de tratamento para deficiência de alfa-1 antittripsina | |
| DK1913004T3 (da) | 8-methoxy-9h-isothiazolo[5,4-b]quinolin-3,4-dioner og beslægtede forbindelser som antiinfektive midler | |
| MX2021001249A (es) | Sal de malonato de epinefrina cristalina. | |
| BR112023018403A2 (pt) | Composições e métodos para tratar policitemia | |
| BRPI0507086A (pt) | método para tratar sintomas de depressão, método monoterapêutico para tratar um paciente quanto aos sintomas de depressão, e, uso de um composto de quetiapina ou um seu sal farmaceuticamente aceitável | |
| BR112018010812A2 (pt) | compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer | |
| BR112015010570B8 (pt) | agentes microbianos, composto e seu uso e composição farmacêutica | |
| BR112022002784A2 (pt) | Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmo |